Comments
Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration (USFDA) to manufacture Azithromycin tablets. Azithromycin tablets are an AB-rated generic equivalent of Pfizer Inc’s Zithromax tablets. The product will be launched in July 2018, the Hyderabad-based company said on Wednesday.
Azithromycin tablets are indicated for the treatment of patients with mild to moderate infections. The approved product has an estimated market size of $132 million for the 12 months ending May 2018, according to IQVIA.
This is the 146th ANDA (including 19 tentative approvals) to be approved out of the Unit VII formulation facility in Hyderabad, used for manufacturing oral products. Aurobindo now has a total of 377 ANDA approvals (344 final approvals, including 17 from Aurolife Pharma LLC and 33 tentative approvals) from USFDA.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.